25 March 2010, Munich and Braunschweig – With InSCREENex GmbH, a new spin-off from the Helmholtz Centre for Infection Research (HZI) enters the market. As an innovative service partner, the company develops customized cells for the biopharmaceutical industry with wide-ranging applications in drug discovery and development.InSCREENex’s core…
November 6, 2008, Munich, Germany - Ascenion GmbH announces today that it is taking an equity position in Certus Pharmaceuticals. Certus is a product-driven biopharmaceutical company based in South San Francisco, CA, U.S.A. Certus has two anti-cancer product platforms with compounds under development that have strong potential to solve…
September 17, 2008, Munich, Germany – The Max-Delbrück Center (MDC), Berlin, Germany, and Ortho Clinical Diagnostics (OCD), Raritan, U.S.A., a Johnson & Johnson Company, have entered into a license agreement on autoantibody targets discovered by Gerd Wallukat, group leader at the MDC, and his team. OCD will use these targets for the…
Munich, January 10, 2008 – Researchers at the Helmholtz Zentrum München – German Research Center for Environmental Health, together with the University of Oregon, USA have developed a new image reconstruction system for computed tomography that produces greater image quality at a lower radiation dose compared with standard systems. With the help…
Munich, December 12th, 2007 – The Helmholtz Centre for Infection Research in Braunschweig (HZI) and AmVac AG entered into a license agreement providing AmVac with exclusive rights to develop and commercialize a synthetic lipopeptide called MALP-2 and its derivatives as vaccine adjuvants. In return, HZI receives upfront and milestone payments, as…
October 18th, 2006, Munich – Ascenion GmbH and the Hanover Medical School (MHH) are to work together closely to patent and market MHH inventions. Ascenion’s life-science focused, interdisciplinary team will assist MHH scientists in evaluating the market potential of their research results, and will recommend a suitable patenting strategy and…
August 2nd, 2006, Munich – Professor Klaus Rajewsky, a world-famous immunologist and geneticist, has chosen Ascenion GmbH as marketing partner for a total of 53 transgenic mice for which he holds the property rights. The mouse strains have been developed mainly as models of immune system disease. They enable research into disease processes as well…
May 23, 2006, Munich – Ascenion GmbH has forged exclusive partnerships with eight research institutes in the Leibniz Association’s life-sciences section. Ascenion will provide comprehensive support in the patenting and commercialization of the institutes’ research results, including scouting, creation and management of stable-value patent…
Munich and Göttingen, February 8, 2005 – With the active support of Ascenion, the German Primate Centre (DPZ) has launched its first spin-off company: Encepharm GmbH.
On a fee-for-service basis, Encepharm offers tailored research services and preclinical studies in the fields of mental illness and neurodegenerative disease. The company addresses…
Munich, September 15, 2004 – The German Primate Centre (DPZ) in Göttingen, the Institute for Molecular Pharmacology (FMP) in Berlin-Buch and the Institute of Plant Genetics and Crop Plant Research (IPK) in Gatersleben have each entered an alliance with Ascenion GmbH in order to further promote the commercial exploitation of their intellectual…
